Publications of Lars Pelz
All genres
Talk (16)
21.
Talk
Scale-Down of an Ortbital Shaken Bioreactor: High Cell Density Cultivation in Perfusion Mode and Virus production. Single-Use Technologies V: Building the Future, Marseille, France (2022)
22.
Talk
Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)
23.
Talk
Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)
24.
Talk
Multiscale model of influenza A virus and defective interfering particle co-infection in animal cell culture. 5th Workshop on Virus Dynamics, virtual (2021)
25.
Talk
Evolution and selection of influenza a virus defective interfering particles in a semi-continuous production system for the use as antiviral. The seventh ESWI Influenza Conference, Virtual Meeting (2020)
26.
Talk
Multiscale model of DIP replication and its effects on influenza A virus infection in animal cell culture. Society for Mathematical Biology 2020 Annual Meeting, Virtual Meeting (2020)
Poster (11)
27.
Poster
Genetically engineered defective interfering particles for antiviral treatment and vaccination. 28th ESACT Meeting, Edingburgh (Scotland) (2024)
28.
Poster
Defective Interfering Particles of Influenza A Virus As Broad-Spectrum Antivirals. 33rd Annual Meeting of the Society for Virology (GfV), Vienna (Austria) (2024)
29.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 32nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)
30.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 8th European Congress of Virology, Gdańsk (Poland) (2023)
31.
Poster
Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
32.
Poster
A Scalable High-Yield Process for Production of Influenza A Virus Defective Interfering Particles and In Vivo Studies. Himmelfahrtstagung on Bioprocess Engineering 2023, Weimar (Germany) (2023)
33.
Poster
Influenza A Virus Chimeric OP7 Defective Interfering Particles: Cell Culture-based Production and In Vivo Antiviral Efficacy. 32nd Annual Meeting of the Society for Virology (GFV), Ulm (Germany) (2023)
34.
Poster
Reverse genetics for Influenza A virus to generate genetically engineered defective interfering particles for antiviral treatment and vaccination. 27th ESACT Meeting, Lisbon (Portugal) (2022)
35.
Poster
Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)
36.
Poster
Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)
37.
Poster
Semi-continuous propagation of influenza A virus and its defective interfering particles - analyzing the dynamic competition to select antiviral candidates. 30th Annual Meeting of the Society for Virology, online (2021)
Thesis - PhD (1)
38.
Thesis - PhD
In-depth characterization and cell culture-based production of influenza A virus defective interfering particles. Dissertation, Otto-von-Guericke-Universität, Magdeburg (2024)
Thesis - Master (1)
39.
Thesis - Master
Optimization of yellow fever virus production with BHK-21 cells. Master, Technische Universität, München (2019)
Preprint (2)
40.
Preprint
Semi-continuous propagation of influenza A virus and its defective interfering particles: analyzing the dynamic competition to select candidates for antiviral therapy. bioRxiv (2021)